Dynamics of liver stiffness predicts complications in patients with HCV related cirrhosis treated with direct-acting antivirals.

[1]  A. Gasbarrini,et al.  Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals , 2021, World journal of hepatology.

[2]  P. Lampertico,et al.  Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. , 2021, Journal of hepatology.

[3]  M. Friedrich-Rust,et al.  Easl Clinical Practice Guidelines (Cpgs) On Non-Invasive Tests For Evaluation Of Liver Disease Severity And Prognosis- 2020 Update. , 2021, Journal of hepatology.

[4]  C. Fernández-Rodríguez,et al.  A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus–Advanced Fibrosis , 2020, Hepatology.

[5]  J. Pawlotsky,et al.  EASL recommendations on treatment of hepatitis C - Final update of the series. , 2020, Journal of hepatology.

[6]  D. Jain,et al.  Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection. , 2020, Archives of pathology & laboratory medicine.

[7]  X. Forns,et al.  Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. , 2020, Journal of hepatology.

[8]  M. Buti,et al.  Non-invasive prediction of liver related events in HCV compensated advanced chronic liver disease patients after oral antivirals. , 2020, Journal of hepatology.

[9]  L. Petraccia,et al.  Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment , 2019, Current medical research and opinion.

[10]  Yi‐Hsiang Huang,et al.  Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents , 2019, Expert review of anti-infective therapy.

[11]  A. Alberti,et al.  Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. , 2018, Journal of hepatology.

[12]  Giovanni Raimondo,et al.  Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. , 2018, Gastroenterology.

[13]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[14]  G. Marasco,et al.  Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. , 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[15]  S. Saitoh,et al.  Shear wave elastography predicts hepatocellular carcinoma risk in hepatitis C patients after sustained virological response , 2018, PloS one.

[16]  T. Takayama,et al.  Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection , 2018, International journal of medical sciences.

[17]  K. Hayashi,et al.  Liver stiffness reduction correlates with histological characteristics of hepatitis C patients with sustained virological response , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[18]  G. Dore,et al.  Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. , 2017, Journal of hepatology.

[19]  Ioan Sporea,et al.  Assessment of biopsy‐proven liver fibrosis by two‐dimensional shear wave elastography: An individual patient data‐based meta‐analysis , 2017, Hepatology.

[20]  X. Forns,et al.  Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. , 2017, Gastroenterology.

[21]  O. Weiland,et al.  Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. , 2017, Journal of hepatology.

[22]  J. Bruix,et al.  Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. , 2016, Journal of hepatology.

[23]  S. Pol.  Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. , 2016, Journal of hepatology.

[24]  G. Ferraioli,et al.  Accuracy of real‐time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: A pilot study , 2012, Hepatology.

[25]  E. Cholongitas,et al.  Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. , 2011, Journal of hepatology.

[26]  S. Sereno,et al.  Long‐term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon , 2003, Journal of viral hepatitis.

[27]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[28]  S. Park,et al.  A Meta-analysis for the Diagnostic Performance of Transient Elastography for Clinically Significant Portal Hypertension. , 2017, Ultrasound in medicine & biology.